Stock ABVX ABIVAX
Add to a list
To use this feature you must be a member
Log inSign up

All News Abivax

Equities

ABVX

FR0012333284

Real-time Euronext Paris
Other stock markets
 06:50:04 2024-04-29 EDT 		5-day change 1st Jan Change
14.92 EUR +0.67% Intraday chart for Abivax +3.61% +51.93%
04-11 Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating MT
04-08 Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating
MT
Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
AQ
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
EQ
ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Abivax reports 2023 financial results and operational update
EQ
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn's and Colitis Organization (ECCO)
AQ
Abivax: presentation on obefazimod at the ECCO congress
CF
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)
EQ
ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality
CI
Abivax appoints new head of quality
CF
Abivax appoints Ana Sharma as Vice President, Global Head of Quality
EQ
Transcript : ABIVAX Société Anonyme - Special Call
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease
AQ
Abivax Modifies Trial Design of Phase 2b Development Program After US FDA Feedback
MT
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
EQ
Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn?s Disease
CI
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
EQ
Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis
CI
Abivax: share price rises after strategic update
CF
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABVX Stock
  4. News Abivax